Jorge Abreu is not a doctor. This is an educational research summary, not a prescription or a personal dosing plan. Study results do not establish that a supplier product is safe or effective for people. Consult a licensed clinician about medical decisions.
01What DAC changes
CJC-1295 with DAC attaches a drug affinity complex intended to extend the compound's activity well beyond the very short half-life of natural GHRH. CJC-1295 without DAC, also called Modified GRF (1-29), is chemically modified for stability but does not carry that extended-activity complex, so its window of action in the body is shorter.
02What has actually been tested
A published trial in healthy adults documented the growth hormone release pattern of CJC-1295 with DAC, giving it a direct human data point most peptides on this site do not have. The no-DAC version's evidence, per the guide reviewed here, is more limited and does not carry the same trial-level documentation.
03Why this matters for stacking claims
Suppliers also sell a CJC-1295 no-DAC plus ipamorelin blend. No clinical or preclinical study of that specific combination was found in the literature reviewed for this site. Marketing language that treats DAC and no-DAC versions as interchangeable, or treats the blend as separately validated, is not supported by the citations on either guide.
Bottom line: If evidence strength is the deciding factor, CJC-1295 with DAC has the more direct human data of the two. That is a statement about documentation, not a recommendation to use either compound.
Read the full guides
Human studies↗
Growth hormone research
CJC-1295 with DAC refers to the specific GHRH-analog-plus-affinity-complex molecule studied in the cited pharmacology trial, developed by a pharmaceutical sponsor for that research program. Reign Peptide's product is a separately manufactured research-chemical vial of the same class labeled for laboratory use, with no confirmed identity match, purity certification tie, or sponsor relationship to the studied compound.
Read the research →
Limited direct evidence↗
Growth hormone research
CJC-1295 No DAC (Modified GRF 1-29) is chemically distinct from CJC-1295 with DAC in that it lacks the affinity-complex modification, which is reported elsewhere in the pharmacology literature to be the feature responsible for extending duration of action; without it, the peptide is expected to behave more like a short-acting GHRH fragment. Reign Peptide's product is a research-chemical vial of this shorter sequence, not the DAC-conjugated molecule and not a pharmaceutical product.
Read the research →
Reign Peptide · Business disclosure
Research product listings
Jorge Abreu is involved in Reign Peptide. Links to Reign are a business connection, not an independent endorsement. Reign lists these products for laboratory research, not human consumption.
Use the listing to check the labeled identity, amount and available batch documentation. A purity result alone does not verify sterility, clinical suitability or equivalence to a medicine used in a trial.
Names and sizes are product labels, not dosing recommendations. Confirm current details with the seller.